The drug distributor also raised its full-year earnings guidance.
CAH Cardinal Health, Inc.
XNYS
269.69
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CAH
$269.69
—
Key stats
$269.69
- 52-Week Range
- $180.45 – $286.29
- YTD
- +31.10%
- IV Rank (30D)
- 53.03
- Straddle Price
- $18.65
- P/C Vol Ratio
- 0.24
- Market Cap
- $60.7B
- Open
- $274.54
- Day Range
- $267.61 – $286.29
- Volume
- 1,204,841
- Prev Close
- $261.93
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.91% |
| Beta vs SPY | 0.65 |
| Cost of Equity (CAPM) | 8.17% (VRP-adj) |
| WACC | 7.86% |
| Volatility Risk Premium | +24.0pp (IV − HV30) |
| Effective Tax Rate | 22.8% |
| Rev. Growth (YoY, DCF input) | +1.3% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.01 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $4.5B |
| Return on Equity (TTM) | -59.5% |
| Book / Price | -4.3% |
| Gross Margin (TTM) | 3.8% |
| FCF Margin (TTM) | 1.8% |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | -3.2% (reverse-DCF on current price) |
| SMA 50 | $239.16 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $249.81 |
| Bollinger Width / SMA20 | 4.4% (drives anchor stability) |
| Net Debt | $4.3B |
| Market Cap | $62B |
Peers used for multiples: AAPL, AMZN, JNJ, LLY, MCK, MSFT, NVDA, WMT
Blended Fair Value
$956.70
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $325.84 | 20% | |
| DDM (Gordon) | $30.26 | 0% | |
| Peer P/E | $214.64 | 5% | median 32.4× · 8 peers |
| Peer EV/EBITDA | $337.53 | 6% | median 21.0× · 8 peers |
| Peer P/B | n/a | 0% | median 10.1× · 7 peers |
| Peer P/S | $8961.54 | 8% | median 8.4× · 8 peers |
| Market Anchor (SMA50) | $239.16 | 41% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $264.58 | 20% | 40 strikes · skew +0.20 |
As of 2026-11-05 · updated
Related
About
- Industry (SIC)
- WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES (5122) · industry map
- Exchange
- XNYS
- Market Cap
- $60.7B
- Employees
- 63,900
- List Date
- 1983-08-04
- CIK
- 0000721371
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- $2.94
- Headquarters
- Dublin, OH
- Homepage
- https://www.cardinalhealth.com
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 1.51% | -0.85% | 0.68% | 6.40% | 4.78% | 4.45% | 2.83% |
| Feb | -5.43% | 5.22% | -0.01% | 6.55% | 3.31% | 4.70% | 2.39% |
| Mar | 15.17% | 7.33% | -0.63% | -1.30% | 6.65% | -8.08% | 3.19% |
| Apr | -0.89% | 0.78% | 7.03% | -8.05% | 3.03% | -9.03% | -1.19% |
| May | -8.90% | -3.03% | 0.06% | -2.84% | 6.12% | 0.80% | -1.30% |
| Jun | 2.75% | -5.70% | 13.37% | -1.20% | 8.21% | 21.73% | 6.53% |
| Jul | 2.49% | 12.17% | -3.30% | 3.14% | -5.58% | -3.51% | 0.90% |
| Aug | -11.89% | 17.24% | -4.70% | 9.02% | -4.63% | -0.42% | 0.77% |
| Sep | -5.61% | -6.51% | -0.87% | -3.61% | 4.95% | -7.04% | -3.12% |
| Oct | -4.40% | 11.67% | 5.35% | -1.64% | 20.79% | 8.86% | 6.77% |
| Nov | -4.92% | 6.34% | 14.43% | 5.26% | 11.59% | 5.98%* | 6.45% |
| Dec | 12.25% | -3.02% | -5.94% | -3.43% | -1.20% | -- | -0.27% |
| Total | -10.80% | 46.11% | 25.81% | 7.03% | 71.90% | 15.63% | 25.95% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $251.34
SMA 50: $239.79
SMA 200: $223.13
Current: $269.59
EMA 12: $254.66
EMA 26: $248.47
MACD: 6.1895 | Signal: 1.0404
BULLISH
ADX (14): 25.89
TREND
+DI: 50.67
−DI: 12.74
Momentum Oscillators
RSI (14): 72.60
OVERBOUGHT
Stoch %K: 72.29
Stoch %D: 70.36
Williams %R: -39.02
Volume & Volatility
BB Upper: $266.51
BB Lower: $236.17
OVERBOUGHT
OBV: 129,277,297
Vol SMA 20: 1,737,244
Vol ROC: -20.89%
ATR: $7.31
True Range: $24.36
HV 20: 27.1%
HV 30: 26.3%
HV 60: 24.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-06T00:00:00 – 2026-11-04T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Strong Q1 earnings beat, driving positive sentiment
- Guidance upgraded, indicating potential for future growth
- Technical indicators show bullish momentum, with MACD and RSI in overbought territory
Primary Risks:
- Overbought conditions may lead to consolidation or correction
- Market volatility could impact stock performance
- Earnings misses or guidance downgrades could negatively impact stock price
Investment Thesis:
Cardinal Health (CAH) has delivered strong Q1 earnings, driving positive sentiment and upgrading guidance. While overbought conditions may lead to consolidation or correction, the company's fundamentals remain strong, making it a potentially attractive investment opportunity.
Recent News Sentiment Impact:
The news headlines suggest a neutral-to-positive sentiment, with some articles highlighting the company's strong start to 2026 and upgraded guidance. However, caution is advised due to the overbought conditions and potential for market volatility.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - Uptrend
Support/Resistance Levels:
- SMA 20: $159.20
- SMA 50: $154.27
- Upper Bollinger Band: $172.42
Momentum Signals:
- RSI (14): 83.08 (overbought)
- MACD: Bullish, with a signal line crossover above the zero line
- Bollinger Bands: Overbought, with price touching the upper band
Volume Analysis:
- Volume SMA 20: 2101609.35
- On-Balance Volume (OBV): 95388142.00
- Volume Rate of Change: 119.90%
News & Sentiment Analysis
Recent Headlines Summary:
The headlines suggest a neutral-to-positive sentiment, with some articles highlighting the company's strong start to 2026 and upgraded guidance.
Sentiment Assessment: NEUTRAL
Catalyst Identification:
- Upcoming earnings release (2025-10-31)
- Fiscal Q1 FY26 revenue beat, driving positive sentiment
Market Narrative:
The news headlines align with the technical signals, suggesting a potential for continued upside momentum. However, caution is advised due to the overbought conditions and potential for market volatility.
Risk & Volatility Assessment
Beta Interpretation: 0.40 (Low risk relative to SPY)
Volatility Regime: Low volatility - stock moves less than market
Options Market Signals:
- IV Rank: 66.2% (Medium)
- Current IV: 56.7%
- Expected Move: $11.20 (29 DTE), 7-DTE: $6.10
- Volume Flow: 61 calls vs 21 puts
- Open Interest: 12 calls vs 21 puts
- Put/Call Volume Ratio: 0.34 (Bullish sentiment)
- Put/Call OI Ratio: 1.75
Downside Protection:
Support levels: SMA 20 ($159.20) and SMA 50 ($154.27)
Market Context & Positioning
Sector Performance: Healthcare sector performing well, with CAH outperforming peers
Institutional Activity: Volume patterns suggesting institutional interest
Correlation Analysis: Stock moves relatively less than market (R-squared interpretation)
Relative Valuation: Position within trading range
Key Levels & Action Items
Critical Price Levels:
- SMA 20 ($159.20) and SMA 50 ($154.27)
- Upper Bollinger Band ($172.42)
Breakout/Breakdown Levels:
- $176.00 (upper end of recent trading range)
- $153.00 (lower end of recent trading range)
Time-Sensitive Catalysts:
- Upcoming earnings release (2025-10-31)
Risk Management:
Stop-loss levels: SMA 20 ($159.20) and SMA 50 ($154.27) Position sizing considerations: Consider reducing position size due to overbought conditions
Generated
News
All CAH news →
Drug distributors went three-for-three, with Cardinal Health putting up the last fall-quarter beat on Thursday, following the examples set by McKesson and Cencora. The post Drug Wholesalers Go Three-For-Three In Earnings Beats, But Only Two Stocks Pop appeared first on…
Mizuho analysts raised its price target ahead of Cardinal Health's earnings. The stock is testing a buy point after topping another entry. The post IBD Stock Of The Day Tests New Buy Point As Indicators Suggest More Upside appeared first on Investor's Business Daily .
Earnings History
15 of 23 under expected move
Avg Expected Move
5.04%
Avg Actual Move
4.62%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-05 | Pre-Market | 4.41% | 3.07% | 0.70x | Within |
| 2021-05-06 | Pre-Market | 5.13% | 7.05% | 1.37x | Exceeded |
| 2021-08-05 | Pre-Market | 4.65% | 14.26% | 3.07x | Exceeded |
| 2021-11-09 | Pre-Market | 7.46% | 0.62% | 0.08x | Within |
| 2022-02-03 | Pre-Market | 5.23% | 0.33% | 0.06x | Within |
| 2022-05-05 | Pre-Market | 6.18% | 4.33% | 0.70x | Within |
| 2022-08-11 | Pre-Market | 5.50% | 5.18% | 0.94x | Within |
| 2022-11-04 | Pre-Market | 4.96% | 5.09% | 1.03x | Exceeded |
| 2023-02-02 | Pre-Market | 5.14% | 0.74% | 0.14x | Within |
| 2023-05-04 | Pre-Market | 5.33% | 0.99% | 0.19x | Within |
| 2023-08-15 | Pre-Market | 4.01% | 2.60% | 0.65x | Within |
| 2023-11-03 | Pre-Market | 4.30% | 6.86% | 1.60x | Exceeded |
| 2024-01-09 | Pre-Market | 2.61% | 1.71% | 0.66x | Within |
| 2024-05-02 | Pre-Market | 3.57% | 0.79% | 0.22x | Within |
| 2024-08-14 | Pre-Market | 5.87% | 3.68% | 0.63x | Within |
| 2024-11-01 | Pre-Market | 4.72% | 7.01% | 1.49x | Exceeded |
| 2025-01-30 | Pre-Market | 4.48% | 0.39% | 0.09x | Within |
| 2025-05-01 | Pre-Market | 5.59% | 3.00% | 0.54x | Within |
| 2025-08-12 | Pre-Market | 3.50% | 7.21% | 2.06x | Exceeded |
| 2025-10-30 | Pre-Market | 4.74% | 15.43% | 3.26x | Exceeded |
| 2026-02-05 | Pre-Market | 5.39% | 9.83% | 1.82x | Exceeded |
| 2026-04-30 | Pre-Market | 6.80% | 4.90% | 0.72x | Within |
| 2026-08-11 | Pre-Market | 6.28% | 1.30% | 0.21x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CAH Options Activity & IV Rank
CAH IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 30.8%
7-DTE IV: 38.1%
Expected Move: $18.65
7-DTE Move: $12.30
Days to Exp: 29 (2026-12-04)
Options Flow
Call Volume: 254
Put Volume: 60
P/C Volume: 0.236
BULLISH
Call OI: 262
Put OI: 64
P/C OI: 0.244
Total OI: 326
ATM Options Pricing
ATM Call: $9.75
ATM Put: $8.90
Call %: 3.6%
Put %: 3.3%
Chain Summary
Chain Volume: 5,426
Chain OI: 32,471
Last Updated: 11/5/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 90th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
90%
vs own history
GEX tilt
+0.61
OI-weighted, today
Vanna tilt
-0.14
δ-sensitivity to IV
Charm tilt
+0.12
δ-decay vs time
? What is this?
· 89 ATM contracts, 9k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
85%
+14.6
pts
EXTREME
ATM 36.1% / Wing 50.7%
30 DTE / 10d
25%
+4.9
pts
EXTREME
ATM 30.7% / Wing 35.6%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)49.5MediumNov 5
IV Rank (30 DTE)53.0MediumNov 5
Straddle Price (30 DTE)$18.65Nov 5
Beta Analysis
Risk Metrics
Beta: -0.0265
Alpha: 35.20%
Correlation: -0.0136
R-Squared: 0.0%
Stock Volatility: 26.0%
Market Volatility: 13.3%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
Notable investors who own CAH
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $130.7M | #110 of 3138 | +59.5% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $60.5M | #525 of 3716 | -62.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $46.1M | #727 of 6285 | -91.7% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $31.4M | #130 of 997 | +14.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $4.3M | #1039 of 4729 | +4.5% | 13F | |
| Glenview Capital Hedge fund Larry Robbins | $4.3M | #41 of 42 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CAH Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 238,500,000 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
30 filers$556.21M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $169.71M | 30.51% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $101.98M | 18.34% | 2026-06-30 |
| 3 | Delta Accumulation, LLC | $50.10M | 9.01% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $40.03M | 7.20% | 2026-06-30 |
| 5 | IMC-Chicago, LLC Custodian | $38.25M | 6.88% | 2026-06-30 |
| 6 | Point72 Asset Management, L.P. | $21.12M | 3.80% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $20.11M | 3.62% | 2025-09-30 |
| 8 | Goldman Sachs Group Inc Custodian | $18.53M | 3.33% | 2026-06-30 |
| 9 | Cubist Systematic Strategies, LLC | $15.23M | 2.74% | 2025-09-30 |
| 10 | Squarepoint Ops LLC | $14.99M | 2.69% | 2026-06-30 |
| 11 | GROUP ONE TRADING LLC Custodian | $12.09M | 2.17% | 2026-06-30 |
| 12 | Millennium Management LLC Custodian | $7.48M | 1.35% | 2026-06-30 |
| 13 | Barclays PLC Custodian | $6.53M | 1.17% | 2026-06-30 |
| 14 | CAPITAL FUND MANAGEMENT S.A. | $5.70M | 1.03% | 2026-06-30 |
| 15 | SG Americas Securities, LLC | $5.44M | 0.98% | 2026-06-30 |
| 16 | TUDOR INVESTMENT CORP ET AL | $4.44M | 0.80% | 2026-06-30 |
| 17 | BNP Paribas Financial Markets Custodian | $3.99M | 0.72% | 2026-06-30 |
| 18 | Walleye Trading LLC | $3.80M | 0.68% | 2026-06-30 |
| 19 | UBS Group AG Custodian | $3.68M | 0.66% | 2026-06-30 |
| 20 | Simplex Trading, LLC Custodian | $2.78M | 0.50% | 2026-06-30 |
| 21 | Verition Fund Management LLC | $2.66M | 0.48% | 2026-06-30 |
| 22 | Two Sigma Investments, LP Custodian | $1.78M | 0.32% | 2026-06-30 |
| 23 | CAPSTONE INVESTMENT ADVISORS, LLC | $1.43M | 0.26% | 2026-06-30 |
| 24 | Walleye Capital LLC | $1.07M | 0.19% | 2026-06-30 |
| 25 | PEAK6 LLC | $950.24K | 0.17% | 2026-06-30 |
27 filers$497.15M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $225.61M | 45.38% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $85.24M | 17.14% | 2026-06-30 |
| 3 | Delta Accumulation, LLC | $81.89M | 16.47% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $36.61M | 7.36% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $13.97M | 2.81% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $13.54M | 2.72% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $5.75M | 1.16% | 2025-09-30 |
| 8 | Squarepoint Ops LLC | $5.35M | 1.08% | 2026-06-30 |
| 9 | CAPITAL FUND MANAGEMENT S.A. | $4.37M | 0.88% | 2026-06-30 |
| 10 | UBS Group AG Custodian | $3.87M | 0.78% | 2026-06-30 |
| 11 | Verition Fund Management LLC | $3.75M | 0.76% | 2026-06-30 |
| 12 | Millennium Management LLC Custodian | $2.78M | 0.56% | 2026-06-30 |
| 13 | Simplex Trading, LLC Custodian | $2.42M | 0.49% | 2026-06-30 |
| 14 | Cubist Systematic Strategies, LLC | $2.34M | 0.47% | 2025-09-30 |
| 15 | Point72 Asset Management, L.P. | $1.95M | 0.39% | 2026-06-30 |
| 16 | Two Sigma Investments, LP Custodian | $1.57M | 0.32% | 2026-06-30 |
| 17 | BNP Paribas Financial Markets Custodian | $1.07M | 0.21% | 2026-06-30 |
| 18 | CAPSTONE INVESTMENT ADVISORS, LLC | $974.00K | 0.20% | 2026-06-30 |
| 19 | READYSTATE ASSET MANAGEMENT LP | $807.70K | 0.16% | 2026-06-30 |
| 20 | CREDIT INDUSTRIEL ET COMMERCIAL | $593.90K | 0.12% | 2026-06-30 |
| 21 | Groupe la Francaise | $593.23K | 0.12% | 2026-06-30 |
| 22 | Qube Research & Technologies Ltd | $570.14K | 0.11% | 2026-06-30 |
| 23 | Walleye Trading LLC | $475.12K | 0.10% | 2026-06-30 |
| 24 | Walleye Capital LLC | $356.34K | 0.07% | 2026-06-30 |
| 25 | TUDOR INVESTMENT CORP ET AL | $308.83K | 0.06% | 2026-06-30 |
CAH Insider Trading (Form 4)
Latest: 2026-08-20Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-20 | Aaron E Alt | Chief Financial Officer | Sell (S) | −42,000 | $236.34 | -$9.93M | EDGAR |
| 2026-08-20 | Jessica L Mayer | Chief Legal/Compliance Officer | Sell (S) | −29,436 | $236.19 | -$6.95M | EDGAR |
| 2026-08-20 | Mary C. Scherer | Chief Accounting Officer | Sell (S) | −2,302 | $237.39 | -$546.5K | EDGAR |
| 2026-08-20 | Deborah Weitzman | CEO, PSS Segment | Sell (S) | −7,354 | $235.45 | -$1.73M | EDGAR |
| 2026-08-20 | Jason M. Hollar | Chief Executive Officer | Sell (S) | −124,529 | $235.89 | -$29.38M | EDGAR |
| 2026-08-20 | Michelle D. Greene | Chief Information Officer | Sell (S) | −11,650 | $235.72 | -$2.75M | EDGAR |
| 2026-08-20 | Stephen M Mason | CEO, GMPD Segment | Sell (S) | −35,000 | $236.40 | -$8.27M | EDGAR |
| 2026-08-18 | Deborah Weitzman | CEO, PSS Segment | Mixed | −22,445 | $235.17 | -$7.00M | EDGAR |
| 2026-08-18 | Jason M. Hollar | Chief Executive Officer | Mixed | −72,833 | $235.17 | -$24.33M | EDGAR |
| 2026-08-18 | Mary C. Scherer | Chief Accounting Officer | Mixed | −992 | $235.17 | -$413.2K | EDGAR |
| 2026-08-18 | Stephen M Mason | CEO, GMPD Segment | Mixed | −19,421 | $235.17 | -$5.95M | EDGAR |
| 2026-08-18 | Aaron E Alt | Chief Financial Officer | Mixed | −22,651 | $235.17 | -$7.23M | EDGAR |
| 2026-08-18 | Michelle D. Greene | Chief Information Officer | Mixed | −7,480 | $235.17 | -$2.36M | EDGAR |
| 2026-08-18 | Valerie Christine Pitteroff | Chief Human Resources Officer | Mixed | +1,125 | $235.17 | -$435.5K | EDGAR |
| 2026-08-18 | Jessica L Mayer | Chief Legal/Compliance Officer | Mixed | −18,907 | $235.17 | -$5.95M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CAH Insider Holdings
20 insiders · @ $269.59
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jason M. Hollar | Chief Executive Officer | 235,132 | $63.39M | -$58.77M | 18 | 2026-08-20 |
| 2 | Deborah Weitzman | CEO, PSS Segment | 78,182 | $21.08M | -$9.45M | 16 | 2026-08-20 |
| 3 | Gregory B Kenny | Director | 64,194 | $17.31M | -$1.19M | 30 | 2025-11-06 |
| 4 | Jessica L Mayer | Chief Legal/Compliance Officer | 58,612 | $15.80M | -$20.19M | 31 | 2026-08-20 |
| 5 | Stephen M Mason | CEO, GMPD Segment | 49,961 | $13.47M | -$27.82M | 18 | 2026-08-20 |
| 6 | Aaron E Alt | Chief Financial Officer | 47,152 | $12.71M | -$17.88M | 11 | 2026-08-20 |
| 7 | Patricia Hemingway Hall | Director | 28,645 | $7.72M | -$918.9K | 15 | 2026-04-17 |
| 8 | Nancy Killefer | Director | 27,624 | $7.45M | $0 | 11 | 2025-11-06 |
| 9 | Akhil Johri | Director | 22,868 | $6.16M | $0 | 8 | 2025-11-06 |
| 10 | David C Evans | Director | 15,373 | $4.14M | $0 | 7 | 2025-11-06 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CAH Board & Officers
As of SEC filings through Aug 20, 2026Directors 10
- Patricia Hemingway Hall · since Sep 12, 2013
- Nancy Killefer · since Sep 14, 2015
- Akhil Johri · since Feb 7, 2018
- David C Evans · listed since Jul 2020
- Sheri H. Edison · since Sep 1, 2020
- Christine Mundkur · since Sep 6, 2022
- Michelle Brennan · since Sep 6, 2022
- Robert Azelby · since Mar 1, 2024
- Robert W Musslewhite · since Mar 7, 2025
- Sudhakar Ramakrishna · since Mar 7, 2025
Officers 9
- Jason M. Hollar · Chief Executive Officer · listed since May 2023
- Deborah Weitzman · CEO, PSS Segment · listed since Aug 2024
- Stephen M Mason · CEO, GMPD Segment · listed since Aug 2024
- Aaron E Alt · Chief Financial Officer · since Feb 10, 2023
- Ola M Snow · Chief Human Resources Officer · since Sep 28, 2018
- Jessica L Mayer · Chief Legal/Compliance Officer · since Mar 22, 2019
- Michelle D. Greene · Chief Information Officer · since Aug 26, 2022
- Mary C. Scherer · Chief Accounting Officer · since Sep 1, 2022
- Valerie Christine Pitteroff · Chief Human Resources Officer · listed since Jan 2026
Changes in the last 10 years (45)
| Mar 17, 2026 | The company announced the departure of Gregory B Kenny from the board in an SEC filing |
| Jan 20, 2026 | Valerie Christine Pitteroff listed as Chief Human Resources Officer (previously CHRO) in SEC filings |
| Dec 29, 2025 | Valerie Christine Pitteroff became CHRO |
| Mar 7, 2025 | Sudhakar Ramakrishna became a director |
| Mar 7, 2025 | Robert W Musslewhite became a director |
| Sep 6, 2024 | The company announced the departure of Sujatha Chandrasekaran from the board in an SEC filing |
| Sep 6, 2024 | The company announced the departure of Steven Barg from the board in an SEC filing |
| Aug 14, 2024 | Stephen M Mason listed as CEO, GMPD Segment (previously CEO, Medical Segment) in SEC filings |
| Aug 14, 2024 | Deborah Weitzman listed as CEO, PSS Segment (previously CEO, Pharmaceutical Segment) in SEC filings |
| Mar 1, 2024 | Robert Azelby became a director |
| Aug 10, 2023 | The company announced the departure of Carrie Smith Cox from the board in an SEC filing |
| May 17, 2023 | Jason M. Hollar listed as Chief Executive Officer (previously Chief Financial Officer) in SEC filings |
| Feb 10, 2023 | Aaron E Alt became Chief Financial Officer |
| Sep 19, 2022 | Deborah Weitzman became CEO, Pharmaceutical Segment |
| Sep 8, 2022 | The company announced the departure of Victor L. Crawford as CEO, Pharmaceutical Segment in an SEC filing |
| Sep 6, 2022 | Sujatha Chandrasekaran became a director |
| Sep 6, 2022 | Steven Barg became a director |
| Sep 6, 2022 | Michelle Brennan became a director |
| Sep 6, 2022 | Christine Mundkur became a director |
| Sep 1, 2022 | Mary C. Scherer became Chief Accounting Officer |
| Aug 26, 2022 | Michelle D. Greene became Chief Information Officer |
| Aug 7, 2022 | The company announced the departure of Michael C Kaufmann from the board in an SEC filing |
| Aug 7, 2022 | The company announced the departure of Michael C Kaufmann as CEO in an SEC filing |
| Sep 1, 2020 | Sheri H. Edison became a director |
| Sep 1, 2020 | Patricia M English became Chief Accounting Officer |
| Jul 8, 2020 | David C Evans no longer listed as Chief Financial Officer in SEC filings |
| Jul 8, 2020 | David C Evans first listed as a director in an SEC filing |
| May 26, 2020 | Jason M. Hollar became Chief Financial Officer |
| Sep 1, 2019 | John H Weiland became a director |
| Sep 1, 2019 | Dean A Scarborough became a director |
| Sep 1, 2019 | David C Evans became Chief Financial Officer |
| Aug 19, 2019 | Jon L Giacomin reported in an SEC filing no longer being CEO, Medical Segment |
| Aug 16, 2019 | Stephen M Mason became CEO, Medical Segment |
| Mar 22, 2019 | Jessica L Mayer became Chief Legal/Compliance Officer |
| Feb 4, 2019 | Brian S Rice became Chief Information Officer |
| Dec 10, 2018 | J Michael Losh first listed as a director in an SEC filing |
| Nov 12, 2018 | Victor L. Crawford became CEO, Pharmaceutical Segment |
| Sep 28, 2018 | Ola M Snow became Chief Human Resources Officer |
| Sep 5, 2018 | Patricia Morrison reported in an SEC filing no longer being Chief Information Officer |
| Feb 20, 2018 | Jon L Giacomin listed as CEO, Medical Segment (previously CEO, Pharmaceutical Segment) in SEC filings |
| Feb 7, 2018 | Akhil Johri became a director |
| Jan 23, 2018 | Michael C Kaufmann listed as CEO (previously CFO) in SEC filings |
| Jan 23, 2018 | Michael C Kaufmann first listed as a director in an SEC filing |
| Jan 1, 2018 | Jorge M Gomez became Chief Financial Officer |
| Jan 3, 2017 | Michele Holcomb became EVP - Strategy & Corp. Dev. |
Not reported recently (18)
- Bruce Downey · Last reported as a director in an SEC filing dated Aug 8, 2023
- Dean A Scarborough · Last reported as a director in an SEC filing dated Oct 19, 2022
- Michele Holcomb · Last reported as EVP - Strategy & Corp. Dev. in an SEC filing dated Aug 17, 2022
- Brian S Rice · Last reported as Chief Information Officer in an SEC filing dated Aug 17, 2022
- Patricia M English · Last reported as Chief Accounting Officer in an SEC filing dated Aug 17, 2022
- John H Weiland · Last reported as a director in an SEC filing dated Nov 15, 2021
- J Michael Losh · Last reported as a director in an SEC filing dated Oct 18, 2021
- Calvin Darden · Last reported as a director in an SEC filing dated Nov 10, 2020
- Stuart G Laws · Last reported as SVP & Chief Accounting Officer in an SEC filing dated Aug 17, 2020
- Colleen F. Arnold · Last reported as a director in an SEC filing dated Nov 13, 2019
- Craig S Morford · Last reported as Chief Legal/Compliance Officer in an SEC filing dated Dec 6, 2018
- Jorge M Gomez · Last reported as Chief Financial Officer in an SEC filing dated Nov 13, 2018
- George S Barrett · Last reported as a director in an SEC filing dated Aug 16, 2018
- Pamela O. Kimmet · Last reported as Chief Human Resources Officer in an SEC filing dated Aug 16, 2018
- David J Anderson · Last reported as a director in an SEC filing dated Jan 17, 2018
- Clayton M Jones · Last reported as a director in an SEC filing dated Nov 16, 2017
- David P King · Last reported as a director in an SEC filing dated Nov 9, 2017
- Donald M Casey Jr. · Last reported as CEO, Medical Segment in an SEC filing dated Sep 18, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CAH Proposed Insider Sales (Form 144)
Latest: 2026-08-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
7 filings
· $59.5M notice value
· 7 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Jason Hollar (1, $29.4M) · Aaron Alt (1, $9.9M) · Stephen Mason (1, $8.3M) · Jessica Mayer (1, $7.0M) · Michelle Greene (1, $2.7M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Mary Scherer | Officer | 2,302 | $546.5K | 2026-08-19 | Merrill | — | EDGAR |
| 2026-08-18 | Aaron Alt | Officer | 42,000 | $9.93M | 2026-08-18 | Merrill | — | EDGAR |
| 2026-08-18 | Michelle Greene | Officer | 11,650 | $2.75M | 2026-08-18 | Merrill | — | EDGAR |
| 2026-08-18 | Deborah Weitzman | Officer | 7,354 | $1.73M | 2026-08-18 | Merrill | — | EDGAR |
| 2026-08-18 | Jessica Mayer | Officer | 29,436 | $6.95M | 2026-08-18 | Merrill | — | EDGAR |
| 2026-08-18 | Stephen Mason | Officer | 35,000 | $8.27M | 2026-08-18 | Merrill | — | EDGAR |
| 2026-08-18 | Jason Hollar | Officer | 124,529 | $29.36M | 2026-08-18 | Merrill | — | EDGAR |
| 2026-06-08 | Gregory Kenny | Former Director | 43,542 | $8.88M | 2026-06-08 | Merrill Lynch | — | EDGAR |
| 2026-02-27 | Michelle Greene | officer | 2,746 | $627.4K | 2026-02-27 | Merrill | — | EDGAR |
| 2026-02-18 | Aaron Alt | Officer | 2,328 | $525.0K | 2026-02-18 | Merrill Lynch | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-04-30
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-30 | 0000721371-26-000017 | EDGAR |
| 2026-03-23 | 0000721371-26-000013 | EDGAR |
| 2026-03-05 | 0000721371-26-000010 | EDGAR |
| 2026-02-05 | 0000721371-26-000004 | EDGAR |
| 2026-01-13 | 0000721371-26-000003 | EDGAR |
| 2025-11-06 | 0000721371-25-000133 | EDGAR |
| 2025-10-30 | 0000721371-25-000128 | EDGAR |
| 2025-10-10 | 0000721371-25-000125 | EDGAR |
| 2025-10-03 | 0000721371-25-000122 | EDGAR |
| 2025-08-27 | 0001193125-25-189845 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2025-08-12 | 0000721371-25-000079 | EDGAR |
| 2024-08-14 | 0000721371-24-000056 | EDGAR |
| 2023-08-15 | 0000721371-23-000060 | EDGAR |
| 2022-08-11 | 0000721371-22-000058 | EDGAR |
| 2021-08-16 | 0000721371-21-000080 | EDGAR |
| 2020-08-13 | 0000721371-20-000089 | EDGAR |
| 2019-08-20 | 0000721371-19-000090 | EDGAR |
| 2018-08-22 | 0000721371-18-000077 | EDGAR |
| 2017-08-10 | 0000721371-17-000083 | EDGAR |
| 2016-08-12 | 0000721371-16-000277 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-30 | 0000721371-26-000018 | EDGAR |
| 2026-02-05 | 0000721371-26-000006 | EDGAR |
| 2025-10-30 | 0000721371-25-000130 | EDGAR |
| 2025-05-01 | 0000721371-25-000038 | EDGAR |
| 2025-01-30 | 0000721371-25-000013 | EDGAR |
| 2024-11-01 | 0000721371-24-000121 | EDGAR |
| 2024-05-02 | 0000721371-24-000038 | EDGAR |
| 2024-02-01 | 0001628280-24-002813 | EDGAR |
| 2023-11-03 | 0000721371-23-000084 | EDGAR |
| 2023-05-04 | 0001628280-23-015775 | EDGAR |
ETF Holders
361 ETFs hold CAH
25 shown · $9.84B total exposure · 0.14% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.07% | $1.6B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.08% | $1.4B | — | 2026-09-30 |
| 3 | VO Vanguard Morningstar Mid-Cap ETF | Vanguard | 0.51% | $1.1B | — | 2026-09-30 |
| 4 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.09% | $786.9M | $886.8B | 2026-11-03 |
| 5 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.09% | $723.4M | $804.8B | 2026-11-03 |
| 6 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.20% | $493.0M | — | 2026-09-30 |
| 7 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.88% | $433.0M | $49.1B | 2026-11-03 |
| 8 | BLCR iShares Large Cap Core Active ETF | iShares (BlackRock) | 4.01% | $389.0M | $9.8B | 2026-11-03 |
| 9 | VOE Vanguard Morningstar Mid-Cap Value ETF | Vanguard | 0.88% | $323.1M | — | 2026-09-30 |
| 10 | VIG Vanguard Dividend Appreciation ETF | Vanguard | 0.23% | $292.8M | — | 2026-09-30 |
| 11 | COWZ Pacer US Cash Cows 100 ETF | Nport | 1.47% | $274.5M | — | 2026-07-31 |
| 12 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.43% | $251.5M | $58.8B | 2026-11-03 |
| 13 | VYM Vanguard High Dividend Yield ETF | Vanguard | 0.22% | $211.9M | — | 2026-09-30 |
| 14 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.21% | $209.2M | — | 2026-11-03 |
| 15 | NOBL ProShares S&P 500 Dividend Aristocrats ETF | ProShares | 1.40% | $173.8M | — | 2026-11-04 |
| 16 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.09% | $163.6M | $181.7B | 2026-11-03 |
| 17 | VHT Vanguard Health Care ETF | Vanguard | 0.73% | $159.2M | — | 2026-09-30 |
| 18 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.83% | $152.5M | $18.5B | 2026-11-03 |
| 19 | RWL Invesco S&P 500 Revenue ETF | Invesco | 1.32% | $137.0M | — | 2026-11-03 |
| 20 | VFLO VictoryShares Free Cash Flow ETF | Nport | 1.55% | $120.4M | — | 2026-06-30 |
| 21 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.08% | $102.0M | $120.5B | 2026-11-03 |
| 22 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.19% | $98.2M | $50.6B | 2026-11-03 |
| 23 | SDY State Street® SPDR® S&P® Dividend ETF | SPDR (State Street) | 0.40% | $88.7M | $22.3B | 2026-11-03 |
| 24 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.08% | $76.4M | $97.0B | 2026-11-03 |
| 25 | SPYV State Street® SPDR® Portfolio S&P 500® Value ETF | SPDR (State Street) | 0.19% | $74.9M | $38.6B | 2026-11-03 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
41.15
TTM Diluted EPS
$6.55
TTM Revenue
$250.74B
TTM Net Income
$1.55B
TTM Op. Cash Flow
$5.01B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-03-31 | $60.94B | $399.00M | $1.69 | $1.82B |
| Q2 '26 | 2025-12-31 | $65.63B | $467.00M | $1.97 | $686.00M |
| Q1 '26 | 2025-09-30 | $64.01B | $450.00M | $1.88 | $973.00M |
| Q4 '25 | 2025-06-30 | $60.16B | $239.00M | $1.01 | $1.53B |
| Q3 '25 | 2025-03-31 | $54.88B | $506.00M | $2.10 | $2.92B |
| Q2 '25 | 2024-12-31 | $55.26B | $400.00M | $1.65 | $-396.00M |
| Q1 '25 | 2024-09-30 | $52.28B | $416.00M | $1.70 | $-1.65B |
| Q4 '24 | 2024-06-30 | $59.87B | $235.00M | $0.95 | $2.08B |
| Q3 '24 | 2024-03-31 | $54.87B | $261.00M | $1.07 | $-27.00M |
| Q2 '24 | 2023-12-31 | $57.44B | $368.00M | $1.50 | $1.18B |
| Q1 '24 | 2023-09-30 | $54.65B | $-12.00M | $-0.05 | $528.00M |
| Q4 '23 | 2023-06-30 | $53.42B | $5.00M | $0.03 | $863.00M |
Q3 2026 • period ending 2026-03-31 • filed 2026-04-30
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
41.15
P/B
—
P/S
0.26
EV/EBITDA
17.22
EV/Sales
0.27
ROE
—
ROA
2.7%
Div Yield
0.84%
FCF Yield
7.79%
Debt/Equity
—
Current Ratio
—
Market Cap
$64.29B
as of 2026-11-05
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.68M
SI % of Float
3.32%
Days to Cover
4.99
Short Vol Ratio
64.2%
Free Float
231.28M
Float %
99.9%
Short interest 2026-10-15 • Short volume 2026-11-04 • Float 2026-09-22